Plant PR-5 proteins as mammalian therapeutic agents
The Proteins of the PR-5 family having a lectin-like β barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like β barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional homologues of adiponectin and control adiponectin response in mammals. PR-5 proteins having a lectin-like β barrel domain, for example osmotin, can be used in the treatment of conditions in mammals which are the result of activation or inhibition of adiponectin receptor-mediated metaboloic pathways. PR-5 proteins having a lectin-like β barrel domain, nucleic acids encoding such proteins, and receptors that specifically bind such proteins, can also be used in screening and rational design of new therapeutic agents for use in mammals.
1. A method for treating a mammal suffering from disorder selected from the group consisting of type II diabetes, insulin resistance, hyperlipidemia, arteriosclerosis, and heart disease, said method comprising administering to the mammal an isolated PR-5 protein, wherein said type II diabetes, insulin resistance, hyperlipidemia, arteriosclerosis, or heart disease is treated.
2. The method of claim 1 , wherein the disorder is type II diabetes.
3. The method of claim 1 , wherein the disorder is insulin resistance.
4. The method of claim 1 , wherein the disorder is hyperlipidemia.
5. The method of claim 1 , wherein the disorder is arteriosclerosis.
6. The method of claim 1 , wherein the disorder is heart disease.
7. The method of claim 1 , wherein the PR-5 protein is osmotin.
8. The method of claim 1 , wherein the PR-5 protein is osmotin.
9. A method for treating a mammalian condition caused by an implicated adiponectin receptor-mediated pathway, said method comprising:
identifying a mammal suffering from a mammalian condition selected from at least one of type II diabetes, insulin resistance, hyperlipidemia, arteriosclerosis and heart disease; and
administering osmotin to the mammal,
wherein said type II diabetes, insulin resistance, hyperlipidemia, arteriosclerosis, or heart disease is treated.